// App-Quantinova.ai

BSH2020‐EP‐092 : Safety, efficacy and tolerability of the NORDIC regimen in the front‐line treatment of transplant‐eligible patients with mantle cell lymphoma

Researchers

Presenter

  • J. Tobin

Principal Investigators

  • A. Smith

  • C. Millar

  • J. Addada

  • J. Lala

  • H. Clarke

  • M. Ruparelia

Medical Centers

  • Department of Hematology,

  • Department of Pathology, Blood Bank, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Infectious Diseases (ID)

  • Oncology (ONC)

  • Central Nervous System (CNS)

Disease

  • Mantle cell lymphoma

  • Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Lymphomas

  • Sepsis

  • Stroke

Biomarkers

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bendamustine

  • Cytarabine liposomal

  • Ibrutinib

  • Cisplatin

  • Rituximab

Outcome

  • N/A

Study Design

  • Multinational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved